Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2024-01-18 00:00:00 ET · period of report 2024-01-16 · accession 0000950170-24-005380 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-01-18 | 2024-01-16 | BBIO | Valantine Hannah | Dir | S - Sale+OE | $37.97 | -2,915 | 1,764 | -62% | -$110.7K |
| DT | 2024-01-18 | 2024-01-16 | BBIO | Valantine Hannah | Dir | M - OptEx | $8.45 | +2,915 | 4,679 | +165% | +$24.6K |
| DT | 2024-01-18 | 2024-01-16 | BBIO | Valantine Hannah | Dir | M - OptEx | $0.00 | -2,915 | 96.2K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-16 | S | D | 2,915 | $37.97 | 1,764 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-16 | M | A | 2,915 | $8.45 | 4,679 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2024-01-16 | M | D | 2,915 | $0.00 | 96,176 | D | $8.45 · — to 2032-06-22 | 2,915 Common Stock | (F2) 1/3rd of the shares underlying the option vested on June 22, 2023; thereafter, 1/3rd of the underlying shares vest on an annual basis, so that all of the underlying shares will be vested on June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. |